These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32083236)

  • 1. Differential Pain-Related Behaviors and Bone Disease in Immunocompetent Mouse Models of Myeloma.
    Diaz-delCastillo M; Kamstrup D; Olsen RB; Hansen RB; Pembridge T; Simanskaite B; Jimenez-Andrade JM; Lawson MA; Heegaard AM
    JBMR Plus; 2020 Feb; 4(2):e10252. PubMed ID: 32083236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
    Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
    Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
    Oyajobi BO; Mundy GR
    Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone.
    Westhrin M; Holien T; Zahoor M; Moen SH; Buene G; Størdal B; Hella H; Yuan H; de Bruijn JD; Martens A; Groen RW; Bosch F; Smith U; Sponaas AM; Sundan A; Standal T
    JBMR Plus; 2020 Jan; 4(1):e10247. PubMed ID: 31956851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unwrapping microcomputed tomographic images for measuring cortical osteolytic lesions in the 5T2 murine model of myeloma treated by bisphosphonate.
    N'Diaye M; Libouban H; Aguado E; Bouvard B; Audran M; Chappard D
    Micron; 2015 Jan; 68():107-114. PubMed ID: 25464148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
    Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
    J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A murine model of myeloma that allows genetic manipulation of the host microenvironment.
    Fowler JA; Mundy GR; Lwin ST; Lynch CC; Edwards CM
    Dis Model Mech; 2009; 2(11-12):604-11. PubMed ID: 19779066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma
    Zangari M; Yoo H; Shin IJ; Yoon D; Suva LJ
    J Bone Oncol; 2018 Sep; 12():19-22. PubMed ID: 29556454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.
    Paton-Hough J; Tazzyman S; Evans H; Lath D; Down JM; Green AC; Snowden JA; Chantry AD; Lawson MA
    J Bone Miner Res; 2019 May; 34(5):783-796. PubMed ID: 30320927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.
    Sharma R; Williams PJ; Gupta A; McCluskey B; Bhaskaran S; Muñoz S; Oyajobi BO
    Oncotarget; 2015 Aug; 6(25):21589-602. PubMed ID: 26009993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease.
    Adamik J; Roodman GD; Galson DL
    JBMR Plus; 2019 Mar; 3(3):e10183. PubMed ID: 30918921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
    Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.
    Pagnotti GM; Chan ME; Adler BJ; Shroyer KR; Rubin J; Bain SD; Rubin CT
    Bone; 2016 Sep; 90():69-79. PubMed ID: 27262776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
    Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
    PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Single Versus Group μCT on the Detection of Trabecular and Cortical Disease Phenotypes in Mouse Bones.
    Kohler R; Tastad CA; Stacy AJ; Swallow EA; Metzger CE; Allen MR; Wallace JM
    JBMR Plus; 2021 Apr; 5(4):e10473. PubMed ID: 33869991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Improved Animal Model of Multiple Myeloma Bone Disease.
    Mehdi SH; Morris CA; Lee JA; Yoon D
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
    Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
    J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.
    Oyajobi BO; Muñoz S; Kakonen R; Williams PJ; Gupta A; Wideman CL; Story B; Grubbs B; Armstrong A; Dougall WC; Garrett IR; Mundy GR
    Mol Cancer Ther; 2007 Jun; 6(6):1701-8. PubMed ID: 17541032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.